Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes

Amy Willis, Eun Joo Jung, Therese Wakefield, Xinbin Chen

Research output: Contribution to journalArticle

162 Citations (Scopus)

Abstract

Mutation of the p53 tumor suppressor gene is the most common genetic alteration in human cancer. A majority of these mutations are missense mutations in the DNA-binding domain. As a result, the mutated p53 gene encodes a full-length protein incapable of transactivating its target genes. In addition to this loss of function, mutant p53 can have a dominant negative effect over wild-type p53 and/or gain of function activity independently of the wild-type protein. To better understand the nature of the tumorigenic activity of mutant p53, we have investigated the mechanism by which mutant p53 can exert a dominant negative effect. We have established several stable cell lines capable of inducibly expressing a p53 mutant alone, wild-type p53 alone, or both proteins concurrently. In this context, we have used chromatin immunoprecipitation to determine the ability of wild-type p53 to bind to its endogenous target genes in the presence of various p53 mutants. We have found that p53 missense mutants markedly reduce the binding of wild-type p53 to the p53 responsive element in the target genes of p21, MDM2, and PIG3. These findings correlate with the reduced ability of wild-type p53 in inducing these and other endogenous target genes and growth suppression in the presence of mutant p53. We also showed that mutant p53 suppresses the ability of wild-type p53 in inducing cell cycle arrest. This highlights the sensitivity and utility of the dual inducible expression system because in previous studies, p53-mediated cell cycle arrest is not affected by transiently overexpressed p53 mutants. Together, our data showed that mutant p53 exerts its dominant negative activity by abrogating the DNA binding, and subsequently the growth suppression, functions of wild-type p53.

Original languageEnglish (US)
Pages (from-to)2330-2338
Number of pages9
JournalOncogene
Volume23
Issue number13
DOIs
StatePublished - Mar 25 2004
Externally publishedYes

Fingerprint

Cell Cycle Checkpoints
Genes
Mutation
Proteins
Chromatin Immunoprecipitation
DNA
p53 Genes
Missense Mutation
Growth
Tumor Suppressor Genes
Cell Line
Neoplasms

Keywords

  • Cell cycle arrest
  • Mutant p53
  • p53
  • Transcription

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. / Willis, Amy; Jung, Eun Joo; Wakefield, Therese; Chen, Xinbin.

In: Oncogene, Vol. 23, No. 13, 25.03.2004, p. 2330-2338.

Research output: Contribution to journalArticle

Willis, Amy ; Jung, Eun Joo ; Wakefield, Therese ; Chen, Xinbin. / Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. In: Oncogene. 2004 ; Vol. 23, No. 13. pp. 2330-2338.
@article{7748b969828a4ded9b58203b46cd4366,
title = "Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes",
abstract = "Mutation of the p53 tumor suppressor gene is the most common genetic alteration in human cancer. A majority of these mutations are missense mutations in the DNA-binding domain. As a result, the mutated p53 gene encodes a full-length protein incapable of transactivating its target genes. In addition to this loss of function, mutant p53 can have a dominant negative effect over wild-type p53 and/or gain of function activity independently of the wild-type protein. To better understand the nature of the tumorigenic activity of mutant p53, we have investigated the mechanism by which mutant p53 can exert a dominant negative effect. We have established several stable cell lines capable of inducibly expressing a p53 mutant alone, wild-type p53 alone, or both proteins concurrently. In this context, we have used chromatin immunoprecipitation to determine the ability of wild-type p53 to bind to its endogenous target genes in the presence of various p53 mutants. We have found that p53 missense mutants markedly reduce the binding of wild-type p53 to the p53 responsive element in the target genes of p21, MDM2, and PIG3. These findings correlate with the reduced ability of wild-type p53 in inducing these and other endogenous target genes and growth suppression in the presence of mutant p53. We also showed that mutant p53 suppresses the ability of wild-type p53 in inducing cell cycle arrest. This highlights the sensitivity and utility of the dual inducible expression system because in previous studies, p53-mediated cell cycle arrest is not affected by transiently overexpressed p53 mutants. Together, our data showed that mutant p53 exerts its dominant negative activity by abrogating the DNA binding, and subsequently the growth suppression, functions of wild-type p53.",
keywords = "Cell cycle arrest, Mutant p53, p53, Transcription",
author = "Amy Willis and Jung, {Eun Joo} and Therese Wakefield and Xinbin Chen",
year = "2004",
month = "3",
day = "25",
doi = "10.1038/sj.onc.1207396",
language = "English (US)",
volume = "23",
pages = "2330--2338",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "13",

}

TY - JOUR

T1 - Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes

AU - Willis, Amy

AU - Jung, Eun Joo

AU - Wakefield, Therese

AU - Chen, Xinbin

PY - 2004/3/25

Y1 - 2004/3/25

N2 - Mutation of the p53 tumor suppressor gene is the most common genetic alteration in human cancer. A majority of these mutations are missense mutations in the DNA-binding domain. As a result, the mutated p53 gene encodes a full-length protein incapable of transactivating its target genes. In addition to this loss of function, mutant p53 can have a dominant negative effect over wild-type p53 and/or gain of function activity independently of the wild-type protein. To better understand the nature of the tumorigenic activity of mutant p53, we have investigated the mechanism by which mutant p53 can exert a dominant negative effect. We have established several stable cell lines capable of inducibly expressing a p53 mutant alone, wild-type p53 alone, or both proteins concurrently. In this context, we have used chromatin immunoprecipitation to determine the ability of wild-type p53 to bind to its endogenous target genes in the presence of various p53 mutants. We have found that p53 missense mutants markedly reduce the binding of wild-type p53 to the p53 responsive element in the target genes of p21, MDM2, and PIG3. These findings correlate with the reduced ability of wild-type p53 in inducing these and other endogenous target genes and growth suppression in the presence of mutant p53. We also showed that mutant p53 suppresses the ability of wild-type p53 in inducing cell cycle arrest. This highlights the sensitivity and utility of the dual inducible expression system because in previous studies, p53-mediated cell cycle arrest is not affected by transiently overexpressed p53 mutants. Together, our data showed that mutant p53 exerts its dominant negative activity by abrogating the DNA binding, and subsequently the growth suppression, functions of wild-type p53.

AB - Mutation of the p53 tumor suppressor gene is the most common genetic alteration in human cancer. A majority of these mutations are missense mutations in the DNA-binding domain. As a result, the mutated p53 gene encodes a full-length protein incapable of transactivating its target genes. In addition to this loss of function, mutant p53 can have a dominant negative effect over wild-type p53 and/or gain of function activity independently of the wild-type protein. To better understand the nature of the tumorigenic activity of mutant p53, we have investigated the mechanism by which mutant p53 can exert a dominant negative effect. We have established several stable cell lines capable of inducibly expressing a p53 mutant alone, wild-type p53 alone, or both proteins concurrently. In this context, we have used chromatin immunoprecipitation to determine the ability of wild-type p53 to bind to its endogenous target genes in the presence of various p53 mutants. We have found that p53 missense mutants markedly reduce the binding of wild-type p53 to the p53 responsive element in the target genes of p21, MDM2, and PIG3. These findings correlate with the reduced ability of wild-type p53 in inducing these and other endogenous target genes and growth suppression in the presence of mutant p53. We also showed that mutant p53 suppresses the ability of wild-type p53 in inducing cell cycle arrest. This highlights the sensitivity and utility of the dual inducible expression system because in previous studies, p53-mediated cell cycle arrest is not affected by transiently overexpressed p53 mutants. Together, our data showed that mutant p53 exerts its dominant negative activity by abrogating the DNA binding, and subsequently the growth suppression, functions of wild-type p53.

KW - Cell cycle arrest

KW - Mutant p53

KW - p53

KW - Transcription

UR - http://www.scopus.com/inward/record.url?scp=1842536849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842536849&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1207396

DO - 10.1038/sj.onc.1207396

M3 - Article

C2 - 14743206

AN - SCOPUS:1842536849

VL - 23

SP - 2330

EP - 2338

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 13

ER -